Effects of the oral, direct factor Xa inhibitor apixaban on routine coagulation assays and anti‐FXa assays

Oral Apixaban for the Treatment of Acute Venous Thromboembolism

Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen et al. · New England Journal of Medicine · 2013 · 2.3K citations · Full text

Medicine, Pharmacokinetics, Pharmacotherapy +12

In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor

Elisabeth Perzborn, Andreas Wilmen, Jens Pohlmann et al. · Journal of Thrombosis and Haemostasis · 2005 · 584 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

Circulation · 2009 · 460 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Discovery of 1-(4-Methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro- 1<i>H</i>-pyrazolo[3,4-<i>c</i>]pyridine-3-carboxamide (Apixaban, BMS-562247), a Highly Potent, Selective, Efficacious, and Orally Bioavailable Inhibitor of Blood Coagulation Factor Xa

Donald Pinto, Michael J. Orwat, Stephanie C. Koch et al. · Journal of Medicinal Chemistry · 2007 · 397 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14

Apixaban, an oral, direct factor <scp>X</scp>a inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Charles Frost, Jessie J. Wang, Sunil Nepal et al. · British Journal of Clinical Pharmacology · 2012 · 363 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13